Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026
Rhea-AI Summary
Apogee Therapeutics (Nasdaq: APGE) said company management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 2:00 p.m. ET.
A live and archived webcast will be available via the News & Events page in the Investors section of Apogee Therapeutics' website.
Positive
- None.
Negative
- None.
News Market Reaction – APGE
In the Feb 5 session, APGE declined 4.24%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 06 | Clinical trial update | Positive | +0.9% | Positive interim Phase 1b APG777 asthma data and 2026 milestone outlook. |
| Jan 05 | Event pre-announcement | Neutral | +2.3% | Scheduled call to present interim APG777 Phase 1b data and milestones. |
| Nov 10 | Earnings and pipeline | Positive | +3.8% | Q3 2025 results, four 2026 readouts, financing and extended cash runway. |
| Nov 10 | Clinical trial update | Positive | +3.8% | Positive interim Phase 1 APG333 data with long half-life and durability. |
| Nov 03 | Conferences participation | Neutral | -4.0% | Announcement of multiple upcoming investor conference appearances. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent clinical and earnings updates have mostly seen positive price alignment, while conference-participation headlines have shown at least one negative divergence.
Over the last few months, Apogee released multiple positive updates. On Nov 10, 2025, interim Phase 1 data for APG333 and Q3 2025 results highlighted a $345M offering and pro forma cash of $913M, with shares up 3.77%. Positive APG333 and APG777 clinical readouts in late 2025 and on Jan 6, 2026 also coincided with gains. In contrast, a Nov 3, 2025 conference-participation announcement saw a -3.96% reaction.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO and BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 2:00 p.m. E.T.
A live and archived webcast of the fireside chat will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.
About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of Atopic Dermatitis (AD), asthma, Eosinophilic Esophagitis (EoE), Chronic Obstructive Pulmonary Disease (COPD) and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Zumilokibart (APG777), the company’s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets, as well as asthma. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit https://apogeetherapeutics.com.
Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
noel.kurdi@apogeetherapeutics.com
Media Contact:
Dan Budwick
1AB
dan@1abmedia.com
